<DOC>
	<DOCNO>NCT02092961</DOCNO>
	<brief_summary>This sub-study OSKIRA-4 study , ( D4300C0004 , NCT01264770 ) explore alternative sensitive modality measure beneficial effect syk inhibition fostamatinib patient active RA . This MRI sub-study report later main study due recruitment delay specialist image site register present entirely separately main study result . This study investigate impact treatment joint activity damage assess synovitis , osteitis , bone erosion joint space narrowing .</brief_summary>
	<brief_title>Randomised Double-Blind , Placebo-Controlled , Parallel Group Study Patients With Active Rheumatoid Arthritis : Magnetic Resonance Imaging Sub-Study</brief_title>
	<detailed_description>Sub-study OSKIRA-4 : A Phase IIB , Multi-Centre , Randomised , Double-Blind , Placebo-Controlled , Parallel Group Study Efficacy Safety Fostamatinib Disodium Monotherapy Compared Placebo Adalimumab Monotherapy Patients Active Rheumatoid Arthritis : Magnetic Resonance Imaging Sub-Study Date : 21 March 2011 Version : 1 Primary objective : Assess efficacy fostamatinib reduce joint synovial disease activity measure : - Change baseline Week 6 ( versus placebo ) OMERACT RAMRIS synovitis score .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Male female age 18 Active rheumatoid arthritis ( RA ) diagnose age 16 Diagnosis within 5 year prior study visit 1 inadequate response treatment maximum 2 DiseaseModifying antirheumatic drug ( DMARD ) therapy , diagnosis within 5 year prior study visit 1 intolerance DMARD therapy , diagnosis within 2 year prior study visit 1 previous use DMARDs 4 swollen joint 4 tender/painful joint ( 28 joint count ) Either Erythrocyte Sedimentation Rate ( ESR ) blood result 28mm/h , CReactive Protein ( CRP ) blood result 10mg/L At least 2 follow : documented history current presence positive rheumatoid factor ( blood test ) , radiographic erosion within 12 month prior study enrolment , presence serum anticyclic citrullinated peptide antibody ( blood test ) Presence least one swollen hand wrist joint . Presence synovitis baseline MRI scan , define least 1 joint RAMRIS synovitis score +1 great . Females pregnant breast feed Poorly control hypertension Liver disease significant liver function test abnormality Certain inflammatory condition ( rheumatoid arthritis ) , connective tissue diseases chronic pain disorder Recent significant cardiovascular disease Significant active recent infection include tuberculosis Previously receive treatment TNF alpha antagonist ( include etanercept , certolizumab , adalimumab , infliximab , golimumab ) anakinra previous treatment biological agent include rituximab , abatacept tocilizumab Use DMARDs within 6 week first study visit Severe renal impairment Neutropenia Unable undergo MRI examination ( e.g . presence pacemaker , defibrillator , implant metallic device anterior interbody cage , aneurysm clip pedicle screw ) Known allergy Gadoliniumbased contrast agent , Tattoos [ area examination contain metallic pigment ] Likely require sedation procedure eGFR less 55 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>OSKIRA</keyword>
	<keyword>fostamatinib</keyword>
	<keyword>CE-MRI</keyword>
	<keyword>DCE-MRI</keyword>
</DOC>